

# Drug Policy

<b>Policy:</b>	<b>20200802</b>	<b>Initial Effective Date: 9/18/2020</b>
<b>Code(s):</b>	<b>HCPCS J9316</b>	<b>Annual Review Date: 03/16/2023</b>
<b>SUBJECT:</b>	<b>Phesgo™ (pertuzumab, trastuzumab and hyaluronidase-zzxf)</b>	<b>Last Revised Date: 03/16/2023</b>

Subject to Site of Care

**Prior approval is required for some or all procedure codes listed in this Corporate Drug Policy.**

## POLICY STATEMENT

This policy involves the use of Phesgo. Prior authorization is recommended for medical benefit coverage of Phesgo. Approval is recommended for those who meet the conditions of coverage in the **Initial Approval and Renewal Criteria, Preferred Drug (when applicable), Dosing/Administration, Length of Authorization, and Site of Care (when applicable)** for the diagnosis provided. The requirement that the patient meet the Criteria and Preferred Drug for coverage of the requested medication applies to the initial authorization only. All approvals for initial therapy are provided for the initial approval duration noted below; if reauthorization is allowed, a response to therapy is required for continuation of therapy.

### I. Length of Authorization <sup>1</sup>

Coverage is provided for 6 months and may be renewed (unless otherwise specified).

- Neoadjuvant and adjuvant therapy may be authorized for a total of 1 year (up to 18 cycles).

### II. Dosing Limits

#### A. Quantity Limit (max daily dose) [NDC Unit]:

- Phesgo (1,200 mg pertuzumab/600 mg trastuzumab/30,000 units hyaluronidase) single-dose vial: 1 vial as initial dose
- Phesgo (600 mg pertuzumab/600 mg trastuzumab/20,000 units hyaluronidase) single-dose vial: 1 vial every 21 days

#### B. Max Units (per dose and over time) [HCPCS Unit]:

- Initial Dose: 180 billable units x 1 dose

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx>

# Drug Policy

- Maintenance Dose: 120 billable units every 21 days

### III. Initial Approval Criteria <sup>1-5</sup>

Coverage is provided in the following conditions:

- Patient is at least 18 years of age; **AND**

#### Universal Criteria <sup>1</sup>

- Left ventricular ejection fraction (LVEF) is within normal limits prior to initiating therapy and will be assessed at regular intervals (e.g., every 3 months) during treatment; **AND**
- Patient has human epidermal growth factor receptor 2 (HER2)-positive\* disease as determined by an FDA-approved or CLIA-compliant test❖; **AND**
- Therapy will not be used in combination with pertuzumab, trastuzumab (or trastuzumab biosimilar product [e.g., Ogivri, Kanjinti, Trazimera, Herzuma, Ontruzant]), or trastuzumab and hyaluronidase-oysk (Herceptin Hylecta); **AND**
- Therapy will not be substituted for or with pertuzumab or any trastuzumab-based formulation (i.e., trastuzumab [or trastuzumab biosimilar product], ado-trastuzumab emtansine, fam-trastuzumab deruxtecan-nxki, trastuzumab-hyaluronidase, etc.); **AND**

#### Breast Cancer † <sup>1-7</sup>

- Used as neoadjuvant therapy; **AND**
  - Patient has locally advanced, inflammatory, or early stage disease; **OR**
- Used as adjuvant therapy; **AND**
  - Patient has locally advanced, inflammatory, or node positive disease **OR** early stage disease at high risk of recurrence; **OR**
- Used for recurrent unresectable or metastatic disease **OR** inflammatory breast cancer with no response to preoperative systemic therapy; **AND**
  - Used as first-line therapy in combination with either paclitaxel or docetaxel; **OR**
  - Used as subsequent therapy ‡; **AND**
    - Patient was previously treated with trastuzumab and chemotherapy; **AND**
    - Patient has not previously received pertuzumab

❖ *If confirmed using an immunotherapy assay* <http://www.fda.gov/companiondiagnostics>

# Drug Policy

† FDA Approved Indication(s); ‡ Compendia recommended Indication(s); Ⓢ Orphan Drug

## \*HER2-positive overexpression criteria:<sup>6,7</sup>

- Immunohistochemistry (IHC) assay 3+; **OR**
- Dual-probe in situ hybridization (ISH) assay HER2/CEP17 ratio  $\geq 2.0$  AND average HER2 copy number  $\geq 4.0$  signals/cell; **OR**
- Dual-probe in situ hybridization (ISH) assay AND concurrent IHC indicating one of the following:
  - HER2/CEP17 ratio  $\geq 2.0$  AND average HER2 copy number  $< 4.0$  signals/cell AND concurrent IHC 3+; **OR**
  - HER2/CEP17 ratio  $< 2.0$  AND average HER2 copy number  $\geq 6.0$  signals/cell AND concurrent IHC 2+ or 3+; **OR**
  - HER2/CEP17 ratio  $< 2.0$  AND average HER2 copy number  $\geq 4.0$  and  $< 6.0$  signals/cell AND concurrent IHC 3+

## IV. Renewal Criteria<sup>1</sup>

Coverage may be renewed based upon the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: cardiotoxicity (e.g., left ventricular dysfunction, cardiomyopathy), pulmonary toxicity (e.g., interstitial pneumonitis), neutropenia, severe infusion-related reactions (e.g., hypersensitivity reactions, anaphylaxis), etc.; **AND**
- Left ventricular ejection fraction (LVEF) within the previous 3 months as follows:
  - Neoadjuvant and adjuvant breast cancer: LVEF is  $\geq 50\%$  OR LVEF has had an absolute decrease of  $< 10\%$  from pre-treatment baseline; **OR**
  - All other indications: LVEF is  $> 45\%$  OR LVEF is 40% to 45% and absolute decrease is  $< 10\%$  from pre-treatment baseline

### Breast Cancer (neoadjuvant or adjuvant treatment)

- Patient has not exceeded a maximum of 1 year of therapy (total of 18 cycles)

# Drug Policy

## V. Dosage/Administration

Indication	Dose
Breast Cancer	<p><b><u>Initial Dose</u></b> Administer 1,200 mg pertuzumab/600 mg trastuzumab/30,000 units hyaluronidase subcutaneously</p> <p><b><u>Maintenance Dose</u></b> Administer 600 mg pertuzumab/600 mg trastuzumab/20,000 units hyaluronidase subcutaneously every 3 weeks</p> <ul style="list-style-type: none"> <li>• Neoadjuvant therapy: administer for 3-6 cycles initially, then continue following surgery to complete 1 year of treatment (up to 18 cycles) or until disease recurrence or unacceptable toxicity</li> <li>• Adjuvant therapy: administer for a total of 1 year (up to 18 cycles) or until disease recurrence or unacceptable toxicity</li> <li>• Recurrent or metastatic breast cancer: administer until disease progression or until unacceptable toxicity</li> </ul>
<p><b><u>Note:</u></b></p> <ul style="list-style-type: none"> <li>– To be administered by a health care professional for subcutaneous use only in the thigh. Do not administer intravenously.</li> <li>– Phesgo has different dosage and administration instructions than intravenous pertuzumab, intravenous trastuzumab, and subcutaneous trastuzumab when administered alone.</li> <li>– Refer to the package insert for timing and sequence of dosing with other chemotherapy.</li> <li>– Refer to the package insert for transitioning from trastuzumab and/or pertuzumab intravenous.</li> </ul>	

## VI. Billing Code/Availability Information

### HCPCS Code:

- J9316 – Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg; 1 billable unit = 10 mg

### NDC(s):

- Phesgo (1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase per 15 mL) single-dose vial: 50242-0245-xx
- Phesgo (600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase per 10 mL) single-dose vial: 50242-0260-xx

# Drug Policy

## VII. References

1. Phesgo [package insert]. South San Francisco, CA; Genentech, Inc; June 2020. Accessed February 2022.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) pertuzumab, trastuzumab and hyaluronidase-zzxf. National Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed February 2022.
3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer 2.2022. National Comprehensive Cancer Network, 2022. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed February 2022.
4. Wolff AC, Hammond EH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. *J Clin Oncol* 2018;36:2105-2122.
5. Tan AR, Im SA, Mattar A, et al. Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study [Abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; *Cancer Res* 2020;80(4 Suppl):Abstract nr PD4-07.
6. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 5/21/20 . Identifier NCT03674112, A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer (PHranceSCa); [Accessed 7/2/20]; Available from: <https://clinicaltrials.gov/ct2/show/NCT03674112?term=NCT03674112&draw=2&rank=1>.
7. Gennari A, André F, Barrios CH, et al.; ESMO Guidelines Committee. Electronic address: [clinicalguidelines@esmo.org](mailto:clinicalguidelines@esmo.org). ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. *Ann Oncol*. 2021 Dec;32(12):1475-1495. doi: 10.1016/j.annonc.2021.09.019. Epub 2021 Oct 19. PMID: 34678411.

---

## FOR MEDICAL BENEFIT COVERAGE REQUESTS:

---

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx>

# Drug Policy

**Prior approval is required for HCPCS Codes J9316**